What changed in this filing

/stocks — the workspaceLOADING

Item 1. Legal Proceedings

2024-11-13 compared with 2024-05-14 · 29 added, 24 removed, 2 unchanged (96% of the section changed)

Legal Proceedings

On January 19, 2024, a purported shareholder

class action complaint, captioned Eric Olmstead v.

To our knowledge, other than described below, neither

the Company nor any of its officers or directors is a party to any material legal proceeding or litigation and such persons know of no

material legal proceeding or contemplated or threatened litigation, other than as described below.

There are no judgments against us or

our officers or directors.

None of our officers or directors has been convicted of a felony or misdemeanor relating to securities or performance

in corporate office.

On January 19, 2024, a purported shareholder class action complaint,

captioned Eric Olmstead v.

3:24-cv-00035, was filed in the U.S.

Court for the District of Nevada, naming the Company and certain of its officers and/or directors as defendants.

On April 15, 2024

the court ordered the motion to consolidate the six pending motions, appointed the lead plaintiff and approved selection of the lead

counsel, now captioned Olmstead v.

BioVie Inc., et al., Case 3:24-cv-0035 LRH-CSD and Way v.

BioVie Inc., et al., Case No.

2:24-cv-00361-LRH-CSD.

The lawsuit alleges that the Company made material misrepresentations and/or omissions of material fact

relating to the Company’s business, operations, compliance, and prospects, including information related to the study and

trial of NE3107, in violation of Sections 10(b) and 20(a) of the Securities Exchange Act of

1934, as amended, and Rule 10b-5 promulgated thereunder.

The class action is on behalf of purchasers of the Company’s

securities during the period from August 5, 2021 through November 29, 2023 and seeks unspecified monetary damages on behalf of the

putative class and an award of costs and expenses, including attorney’s fees.

The Company believes the lawsuit is without merit

and intends to defend the case vigorously.

At this early stage of the proceedings, the Company is unable to make any prediction regarding

the outcome of the litigation.

There are no other judgments against us or our officers

or directors.

None of our officers or directors has been convicted of a felony or misdemeanor relating to securities or performance in

corporate office.

District Court for the District of Nevada, naming

the Company and certain of its officers as defendants.

On February 22, 2024, a second, related putative securities class action was filed

in the same court asserting similar claims against the same defendants, captioned Way v.

2:24-cv-00361.

15, 2024, the court consolidated these two actions under the caption In re BioVie Inc.

Securities Litigation, No.

3:24-cv-00035, appointed

the lead plaintiff, and approved selection of the lead counsel.

On June 21, 2024, the lead plaintiff filed an amended complaint, alleging

that the defendants made material misrepresentations and/or omissions of material fact relating to the Company’s business, operations,

compliance, and prospects, including information related to the NM101 Phase 3 study and trial of bezisterim (NE3107) in mild to moderate

probable AD, in violation of Sections 10(b) and 20(a) of the Exchange Act, and Rule 10b-5 promulgated thereunder.

The class action is

on behalf of purchasers of the Company’s securities during the period from December 7, 2022 through November 28, 2023 and seeks

unspecified monetary damages on behalf of the putative class and an award of costs and expenses, including attorney’s fees.

defendants filed a motion to dismiss the amended complaint on August 21, 2024, and plaintiffs filed their opposition on October 21, 2024.

The defendants’ reply brief is due December 5, 2024.

The defendants believe that the claims are without merit and intend to defend

vigorously against them, but there can be no assurances as to the outcome.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 1. Legal Proceedings